TROLIP Capsule

ក្រុមហ៊ុនផលិតឱសថ:

 

PT Dexa Media, Indonesia

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. TROLIP 100:

    Fenofibrate 100mg

    2. TROLIP 300:

    Fenofibrate 300mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    Trolip is indicated to treatment:

    - Hypercholesterolemia (typeⅡa).

    - Hypertriglyceridemia (typeⅣ).

    - Mix hyperlipidemia (typeⅡb and Ⅲ).

    Dosage and administration:

    Adults

    Initial dose: 100mg 3 times a day or 300mg/day as a single dose.

    If after strict cholesterol diet the concentration of cholesterol stays at > 4g/L, dose can be increased to 100mg 4 times daily.

    Initial dose should be maintained until cholesterol level gets back to normal. If cholesterol level is stabilized, dosage of 100mg twice daily can be given provided that cholesterol level is checked every 3 months. If there is a new increase in the plasma cholesterol concentration, dose should go back to initial dose of 100mg 3 times daily.

    Children

    Over 10 years: maximum 5mg/kg daily.

  • ហាមប្រើ

    - Patients with severe liver and renal dysfunction.

    - Pregnancy and lactation.

    - Hypersensitivity to fenofibrate.

    - Patients with gallbladder disease.

  • ផលរំខាន

    In general, side effects are mid and rarely reported. In prolonged therapy, the following side effects have been reported:

    - Gastrointestinal disturbances about 5%.

    - Headache about 1%.

    - Muscular spasm about 1%.

    - Transient elevation of transaminases and creatin phosphokinase.

    - Skin allergic reactions.

    - Fatigue and vertigo.

  • អន្តរប្រតិកម្ម

    The effect of oral anticoagulant is potentiated by fenofibrate. This increase the risk of haemorrhage through displacement of their binding with plasma protein. Therefore, initial dose therapy with fenofibrate should be reduced to 1/3 of the normal dose. Adjustment of oral anticoagulant dose according to prothrombin time during therapy by fenofibrate and 8 days after its interruption.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    See "Contraindication".

  • ការប្រុងប្រយ័ត្នជាពិសេស

    - For the first year of therapy, serum transaminase should be monitored periodically, every 3 months. Therapy should be discontinue if there is an increase in SGPT concentration >100unit/L.

    - Combination therapy of hepatotoxic substances like perheccillin maleate or IMAO is not recommended.

    - If 3 months after therapy, the reduction of serum concentration of lipid is not satisfactory, other therapeutic) complementary or different) should be considered.

  • សកម្មភាពឱសថ

    Fenofibrate is phyenoxyisobutyric acid. With clofibrate and other fibrate acid derivatives is used as lipid regulator by reducing total plasma cholesterol and triglyceride in healthy subjects and patients with Hyperlipoproteinemia. The main action of fenofibrate is to increase lipoprotein catabolism which is risk in triglyceride by increasing lipase lipoprotein activity.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp